Compounds for the treatment of atropic vaginitis

Camil Castelo‐Branco, María Jesús Cancelo Hidalgo
In: Expert Opinion on Therapeutic Patents · 2008 · vol. 18(12) , pp. 1385–1394 · doi:10.1517/13543770802564464 · W2133482297
article OA: closed CC0
View on OpenAlex View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-09 ⓘ

This review summarizes randomized trial results and patent information for atrophic vaginitis treatments, finding most preparations effective with varying adverse event profiles and lacking long-term safety data.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Background: Atropic vaginitis is the result of a significant decrease in estrogen levels. This frequent complaint is characterized by dryness and inflammation of the vagina with thinning of the urogenital epithelium. The diagnosis is clinical, based on symptoms and physical examination. Clinical manifestations include vaginal dryness, itching, burning, discharge, bleeding, dyspareunia and urinary tract symptoms such as frequency, recurrent infection and discomfort. Different therapies have been shown to effectively manage signs and symptoms. Objective/methods: A Medline (1966 – present) search was performed for randomized trials involving treatments for atropic vaginitis. Additionally, a review of patent lists (http://gb.espacenet.com) was done. Reference lists of papers and patents were reviewed for further references. Conclusion: In this article, the authors summarize the clinical results of the treatments and the patent landscape. Almost all preparations are effective in decreasing signs and symptoms of vaginal atrophy but they differ slightly in their adverse-event profiles. Long-term safety of the preparations is best established for estradiol tablets (1 year) but is lacking for all preparations.

My notes (saved in your browser only)

Condition tags

dyspareunia

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (2)

References (73)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK